Natera (NTRA) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Natera (NTRA) do?
Natera Inc (NTRA) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells circulating cell-free DNA blood tests that detect fetal genetic conditions and monitor tumor recurrence. It analyzes microscopic fragments of DNA circulating in blood to detect fetal abnormalities and cancer recurrences. It is worth $42.04B on the market and sold $2.91B over the last year.
- Market cap
- $42.04B
- P/E ratio
- None (reported a loss)
- Annual sales
- $2.91B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 15, 2026
Brands and businesses behind NTRA
- Signatera: It detects residual cancer DNA from blood draws to help oncologists monitor tumor recurrence, earning diagnostic fee revenue.
- Panorama: It screens maternal blood for fetal chromosomal abnormalities early in pregnancy, earning diagnostic fee revenue from patient testing.
- Horizon: It tests carrier genetic mutations before pregnancy to identify risks of passing disorders to children, charging insurance providers.
- Prospera: It checks blood samples from organ transplant recipients to detect early signs of rejection, earning clinical diagnostic reimbursements.
- Anora: It analyzes miscarriage tissue to help determine the genetic causes of pregnancy loss, earning test reimbursement fees.
NTRA’s flags, in plain English
Each flag is a number from Natera’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Still Climbing
Sales up 42.6% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Stupid Cash
Can pay this year's bills 2.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 13% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Burning Cash
Losing money, profit margin of -5.7%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about NTRA
How big is Natera?
Natera’s market cap is $42.04B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.91B: what customers paid the company over the last year, before any costs.
What is NTRA’s P/E ratio?
NTRA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with NTRA?
Natera faces active patent infringement lawsuits and deceptive advertising disputes with competing diagnostic test providers. That is one risk on Natera’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Natera’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NTRA’s filings on SEC.gov. The Margin Monkey is research, not advice.
